Agentix (Agentix) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Agentix Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Agentix's annualized Gross Profit for the quarter that ended in Dec. 2023 was $0.00 Mil. Agentix's average Total Assets over the quarter that ended in Dec. 2023 was $0.22 Mil. Therefore, Agentix's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.

Agentix Gross-Profit-to-Asset % Historical Data

The historical data trend for Agentix's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agentix Gross-Profit-to-Asset % Chart

Agentix Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Mar23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

0.58

Agentix Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Agentix's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Agentix's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agentix's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agentix's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Agentix's Gross-Profit-to-Asset % falls into.

Agentix Gross-Profit-to-Asset % Calculation

Agentix's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Mar. 2023 )	/	( (Total Assets (A: Aug. 2021 )	+	Total Assets (A: Mar. 2023 ))	/ count )
	=	0	/	( (0.051	+	0.261)	/ 2 )
	=	0	/	0.156
	=	0.00 %

Agentix's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0	/	( (0.334	+	0.112)	/ 2 )
	=	0	/	0.223
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Agentix Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Agentix's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Agentix (Agentix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agentix Corp (OTCPK:AGTX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

32932 Pacific Coast Highway, Suite 14-254, Dana Point, CA, USA, 92629

Website

https://www.agentixcorp.com

Agentix Corp is a biotechnology company. It is engaged in the development and commercialization of novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. Its principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and continue to drive innovations in the endocannabinoid space.

Executives

Thomas E Puzzo	10 percent owner	4216 NE 70TH STREET, SEATTLE WA 98115
Michael Winterhalter	director, 10 percent owner, officer: President, CEO, CFO, Treasurer	32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Grays Peak Ventures Llc	10 percent owner	320 PARK AVE, NEW YORK NY 10022
Scott B Stevens	director, officer: President and Director	9701 WILSHIRE BLVD., SUITE 1000, BEVERLY HILLS CA 90212
Robert K Whalen	director, officer: Secretary and Treasurer	32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Scott Thomas	director	14 MONARCH BEACH PLAZA, SUITE 254, MONARCH BEACH CA 92629
Robert Drust	director	14 MONARCH BEACH PLAZA, SUITE 254, MONARCH BEACH CA 92629
Eric Krogius	director, 10 percent owner	32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Bao Dong Han	10 percent owner	32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629

Agentix (Agentix) Headlines

No Headlines